Clinical study of targeted therapy in the treatment of metastatic non-clear cell renal cell carcinoma
Guiming Zhang,Yao Zhu,Weijie Gu,Hongkai Wang,Fangning Wan,Hailiang Zhang,Guohai Shi,Xiaojian Qin,Chunguang Ma
DOI: https://doi.org/10.3760/cma.j.issn.1000–6702.2015.03.006
2015-01-01
Abstract:Objective To evaluate the efficacy and side effects of targeted therapy in the treatment of metastatic non-clear cell renal cell carcinoma (nccRCC).Methods Data of patients with metastatic renal cell carcinoma (RCC) who received sorafenib (400 mg,twice one day) or sunitinib (50 mg/d,4 weeks on/2 weeks off) as the first-line targeted therapy from Dec.2006 to May.2014 were analyzed retrospectively.Pathological diagnosis indicated 317 clear cell RCC (ccRCC) and 56 nccRCC (29 papillary RCC and 27 other subtypes).Kaplan-Meier method was used to assess overall survival (OS),and log-rank test was performed to compare the difference of median follow-up between the two groups.Side effects were also documented and analyzed in all the patients.Results The follow-up period was 2.7 to 79.9 mon (median:34.3 mon) in the whole group,among which the median follow-up was 36.6 mon in metastatic ccRCC patients and 18.5 mon in nccRCC patients,respectively.The one,two and three-year survival rate in metastatic ccRCC patients were 90.2％,47.9％ and 24.6％,respectively.The one-year survival rate in metastatic nccRCC patients was 60.7％,and only one patient survived over two years.Compared with ccRCC patients,those with nccRCC showed poorer prognosis (P＜0.01).In patients with metastatic papillary RCC,the median follow-up was 18.1 mon and the one-year survival rate was 51.7％,which was worse than those with other subtypes.Analogous to ccRCC,common side effects experienced by nccRCC patients were fatigue,hand-foot syndrome,diarrhea,nausea,rash and hypertension,and there was no significant difference between the two groups (P＞0.05).Conclusions Targeted therapy is efficient in the treatment of metastatic nccRCC patients and the side effects are reversible,although the prognosis is poorer compared with ccRCC.